EP3652318A1 — Engineered immunostimulatory bacterial strains and uses thereof
Assigned to Actym Therapeutics Inc · Expires 2020-05-20 · 6y expired
What this patent protects
The invention relates to immunostimulatory bacteria and pharmaceutical compositions containing the bacteria. The immunostimulatory bacteria according to the invention have one or more characteristics which improve the antitumor activity of the immunostimulatory bacteria. Among th…
USPTO Abstract
The invention relates to immunostimulatory bacteria and pharmaceutical compositions containing the bacteria. The immunostimulatory bacteria according to the invention have one or more characteristics which improve the antitumor activity of the immunostimulatory bacteria. Among the immunostimulatory bacteria of the invention are bacteria, such as Salmonella species, which are modified to be auxotrophic or are auxotrophic for adenosine and / or contain plasmids encoding RNAi, such as an HSR and a microRNAs, which mediate gene disruption and / or the expression of immune control points, such as TREX1, VISTA, PD-11, and genes that affect the immune system. The bacteria contain additional modifications to improve their antitumor activity. The invention also relates to methods of inhibiting growth or reducing the volume of a solid tumor by administering the pharmaceutical compositions.
Drugs covered by this patent
- Palbociclib (palbociclib) · Pfizer Inc.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.